Related references
Note: Only part of the references are listed.The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
Matteo Canale et al.
CANCERS (2022)
Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
Yu Chen et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer
C. C. H. J. Kuijpers et al.
LUNG CANCER (2018)
Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
Charu Aggarwal et al.
JCO PRECISION ONCOLOGY (2018)
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
Robert Brody et al.
LUNG CANCER (2017)
Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies
Qing-Ge Zhu et al.
ONCOTARGET (2017)
The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer
Dan Zhao et al.
SCIENTIFIC REPORTS (2017)
Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations
F. Hsu et al.
CURRENT ONCOLOGY (2017)
Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma
Cheng Lin et al.
CLINICAL LUNG CANCER (2015)
B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer
Yixiang Mao et al.
ONCOTARGET (2015)
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
Mirko Marabese et al.
ONCOTARGET (2015)
Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
Jie Zhang et al.
THORACIC CANCER (2015)
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
Julien Mazieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
PD-L1 gene expression in Japanese lung cancer patients
Hidefumi Sasaki et al.
BIOMEDICAL REPORTS (2013)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Share Paper
